JSCRX
Price
$21.32
Change
+$0.22 (+1.04%)
Updated
Jun 2 closing price
Net Assets
3.5B
WCMLX
Price
$15.23
Change
+$0.18 (+1.20%)
Updated
Jun 2 closing price
Net Assets
52.45M
Interact to see
Advertisement

JSCRX vs WCMLX

Header iconJSCRX vs WCMLX Comparison
Open Charts JSCRX vs WCMLXBanner chart's image
JSCRX vs WCMLX Comparison Chart in %
View a ticker or compare two or three
VS
JSCRX vs. WCMLX commentary
Jun 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JSCRX is a Buy and WCMLX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
JSCRX has more cash in the bank: 3.5B vs. WCMLX (52.4M). JSCRX pays higher dividends than WCMLX: JSCRX (0.10) vs WCMLX (0.00). JSCRX was incepted earlier than WCMLX: JSCRX (22 years) vs WCMLX (7 years). WCMLX (1.79) is less costly to investors than JSCRX (1.56). WCMLX is a more actively managed with annual turnover of: 89.00 vs. JSCRX (62.00). JSCRX has a lower initial minimum investment than WCMLX: JSCRX (0) vs WCMLX (100000). WCMLX annual gain was more profitable for investors over the last year : 25.84 vs. JSCRX (15.61). WCMLX return over 5 years is better than : -0.07 vs. JSCRX (-18.90).
JSCRXWCMLXJSCRX / WCMLX
Total Expense Ratio1.310.99132%
Annual Report Gross Expense Ratio1.561.7987%
Fund Existence22 years7 years-
Gain YTD10.2409.375109%
Front LoadN/AN/A-
Min. Initial Investment0100000-
Min. Initial Investment IRAN/AN/A-
Net Assets3.5B52.4M6,677%
Annual Yield % from dividends0.100.00-
Returns for 1 year15.6125.8460%
Returns for 3 years30.6132.1395%
Returns for 5 years-18.90-0.0728,466%
Returns for 10 years-0.98N/A-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PDSB1.170.03
+2.63%
PDS Biotechnology Corp
NWBI14.160.19
+1.40%
Northwest Bancshares
AFG128.780.51
+0.40%
American Financial Group
TLNCU10.40N/A
N/A
Talon Capital Corp
FULC3.14-3.28
-51.09%
Fulcrum Therapeutics